SEC Form	4
----------	---

Instruction 1(b).

FORM 4

Check this box if no longer subject

to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL
ID Manaka and	0005.000

OMB Number: 0287 3235 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Borgeson Blake (Last) (First) (Last) (First) (Middle) C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET (Street) SALT LAKE UT 84101		Person [*]	2. Issuer Name and Ticker or Trading Symbol <u>RECURSION PHARMACEUTICALS</u> , <u>INC.</u> [RXRX]		ationship of Reporting Pe (all applicable) Director	10% Owner				
		()	3. Date of Earliest Transaction (Month/Day/Year) 01/09/2024		Officer (give title below)	Other (specify below)				
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	,					
		84101			Form filed by More than One Reporting Person					
CITY			Rule 10b5-1(c) Transaction Indication							
(City)	(State)	(Zip)	X Check this box to indicate that a transaction was made pursuan satisfy the affirmative defense conditions of Rule 10b5-1(c). See			lan that is intended to				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction D Code (Instr.		4. Securities Disposed Of			Securities	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)	(Instr. 4)
Class A Common Stock	01/09/2024		S ⁽¹⁾		6,303	D	\$ 13.2124 ⁽²⁾	7,358,169	D	
Class A Common Stock	01/09/2024		S ⁽¹⁾		13,751	D	\$ 13.8117 ⁽³⁾	7,344,418	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

Derivative Security	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number Transaction Code (Instr. 8) Acquires Acquires Acquires of (D) Disposed of (D) (Instr. 3, 4 and 5)		Transaction Code (Instr. 8) Acq (A) Diss of (I (Ins		ion Date, Transaction Code (Instr.		of Expiration Date (Month/Day/Year) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		7. Title Amou Secur Under Deriva Secur 3 and	int of rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

1. Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023.

2. The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from \$12.5 to \$13.495 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

3. The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from \$13.50 to \$14.06 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request

Remarks:

/s/ Jonathan Golightly, attorney-in-fact

01/11/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.